Journal
BLOOD
Volume 129, Issue 18, Pages 2465-2470Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2017-02-692715
Keywords
-
Categories
Funding
- Edward P. Evans Foundation
- National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health [R01 DK102792, R01 HL128239]
- Frederick A. DeLuca Foundation
- Department of Defense Bone Marrow Failure Research Program [BM150092, W81XWH-12-1-0041]
- Josie Robertson Investigator Program
- Starr Foundation [I8-A8-075]
- Leukemia and Lymphoma Society
- Henry & Marilyn Taub Foundation
- Pershing Square Sohn Cancer Research Alliance
- CDMRP [893251, BM150092] Funding Source: Federal RePORTER
Ask authors/readers for more resources
Mutations in RNA splicing factors are the single most common class of genetic alterations in myelodysplastic syndrome (MDS) patients. Although much has been learned about how these mutations affect splicing at a global-and transcript-specific level, critical questions about the role of these mutations in MDS development and maintenance remain. Here we present the questions to be addressed in order to understand the unique enrichment of these mutations in MDS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available